MAP2K7 and endometrial cancer: Based on the prominent role of the RAS/RAF/MEK/ERK pathway in angiogenesis and progression of endometrial cancer [50, 51], a phase II study of sorafenib treatment for advanced endometrial cancer was conducted; however, the results indicated very modest effects only [52].